TLOG (TetraLogic Pharmaceuticals) Debt-to-Equity: -1.00 (As of Sep. 2016)


What is TetraLogic Pharmaceuticals Debt-to-Equity?

TetraLogic Pharmaceuticals TLOG Debt-to-Equity is -1.00 as of Sep. 2016.

TetraLogic Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was $0.00 Mil. TetraLogic Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2016 was $30.81 Mil. TetraLogic Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2016 was $-30.94 Mil. TetraLogic Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2016 was -1.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for TetraLogic Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

TLOG's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

TetraLogic Pharmaceuticals  (OTCPK:TLOG) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

TetraLogic Pharmaceuticals Debt-to-Equity Related Terms

TetraLogic Pharmaceuticals Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for TetraLogic Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TetraLogic Pharmaceuticals Debt-to-Equity Chart

TetraLogic Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
Debt-to-Equity
0.00 -0.07 0.00 0.82 -4.76

TetraLogic Pharmaceuticals Quarterly Data
Dec11 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.12 -4.76 -1.81 -1.35 -1.00

TLOG vs ARGSQ, GTHR, SOAN: Debt-to-Equity Comparison

For the Biotechnology subindustry, TetraLogic Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TetraLogic Pharmaceuticals Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TetraLogic Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where TetraLogic Pharmaceuticals's Debt-to-Equity falls into.


TetraLogic Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

TetraLogic Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 28.279) / -5.941
=-4.76

TetraLogic Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2016 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 30.809) / -30.938
=-1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -1.00 mean?
TetraLogic Pharmaceuticals (TLOG) has a Debt-to-Equity of -1.00 as of Sep. 2016. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TetraLogic Pharmaceuticals and its competitors.
Is TetraLogic Pharmaceuticals' Debt-to-Equity too high?
TetraLogic Pharmaceuticals' current Debt-to-Equity is -1.00.
How does TetraLogic Pharmaceuticals' Debt-to-Equity compare to ARGSQ and GTHR?
TetraLogic Pharmaceuticals' Debt-to-Equity of -1.00 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TetraLogic Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TetraLogic Pharmaceuticals's current Debt-to-Equity is -1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TetraLogic Pharmaceuticals stock overvalued right now?
TetraLogic Pharmaceuticals (TLOG) has a current Debt-to-Equity of -1.00. The current Debt-to-Equity is -1.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For TetraLogic Pharmaceuticals (TLOG), the current Debt-to-Equity is -1.00 as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TetraLogic Pharmaceuticals Business Description

Address 343 Phoenixville Pike, Malvern, PA, USA, 19355
TetraLogic Pharmaceuticals Corp is a biopharmaceutical company. The company is engaged in developing novel small molecule therapeutics in oncology.